Timothy J Martins
Overview
Explore the profile of Timothy J Martins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qin G, Dai J, Chien S, Martins T, Loera B, Nguyen Q, et al.
Clin Cancer Res
. 2024 Apr;
30(12):2659-2671.
PMID: 38619278
Purpose: The inherent genetic heterogeneity of acute myeloid leukemia (AML) has challenged the development of precise and effective therapies. The objective of this study was to elucidate the genomic basis...
2.
Fernandez E, Tomassoni L, Zhang X, Wang J, Obradovic A, Laise P, et al.
bioRxiv
. 2024 Apr;
PMID: 38559080
Diffuse Midline Gliomas (DMGs) are universally fatal, primarily pediatric malignancies affecting the midline structures of the central nervous system. Despite decades of clinical trials, treatment remains limited to palliative radiation...
3.
Halpern A, Martins T, Jonlin E, Dai J, Chien S, Becker P
JCO Precis Oncol
. 2022 Jan;
4:1367-1373.
PMID: 35050791
No abstract available.
4.
Coffey D, Cowan A, DeGraaff B, Martins T, Curley N, Green D, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250400
Materials And Methods: Twenty-five patients with relapsed or refractory MM underwent a screening bone marrow or soft tissue biopsy. Sixteen patients were found to have sufficient plasma cells for HTS....
5.
Czerniecki S, Cruz N, Harder J, Menon R, Annis J, Otto E, et al.
Cell Stem Cell
. 2018 May;
22(6):929-940.e4.
PMID: 29779890
Organoids derived from human pluripotent stem cells are a potentially powerful tool for high-throughput screening (HTS), but the complexity of organoid cultures poses a significant challenge for miniaturization and automation....
6.
Chang C, Kotini A, Olszewska M, Georgomanoli M, Teruya-Feldstein J, Sperber H, et al.
Stem Cell Reports
. 2018 Apr;
10(5):1610-1624.
PMID: 29681544
Connecting specific cancer genotypes with phenotypes and drug responses constitutes the central premise of precision oncology but is hindered by the genetic complexity and heterogeneity of primary cancer cells. Here,...
7.
Lee S, Celik S, Logsdon B, Lundberg S, Martins T, Oehler V, et al.
Nat Commun
. 2018 Jan;
9(1):42.
PMID: 29298978
Cancers that appear pathologically similar often respond differently to the same drug regimens. Methods to better match patients to drugs are in high demand. We demonstrate a promising approach to...
8.
Blau C, Ramirez A, Blau S, Pritchard C, Dorschner M, Schmechel S, et al.
J Natl Compr Canc Netw
. 2016 Jan;
14(1):8-17.
PMID: 26733551
Accelerating cancer research is expected to require new types of clinical trials. This report describes the Intensive Trial of OMics in Cancer (ITOMIC) and a participant with triple-negative breast cancer...
9.
James R, Davidson K, Bosch K, Biechele T, Robin N, Taylor R, et al.
PLoS One
. 2012 Dec;
7(12):e50457.
PMID: 23227175
The Wnt/ß-catenin signaling pathway controls important cellular events during development and often contributes to disease when dysregulated. Using high throughput screening we have identified a new small molecule inhibitor of...
10.
Hothi P, Martins T, Chen L, Deleyrolle L, Yoon J, Reynolds B, et al.
Oncotarget
. 2012 Nov;
3(10):1124-36.
PMID: 23165409
Glioblastoma Multiforme (GBM) continues to have a poor patient prognosis despite optimal standard of care. Glioma stem cells (GSCs) have been implicated as the presumed cause of tumor recurrence and...